Wan, Wen

First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study

Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 87

Use of an AI scribe and electronic health record efficiency

Pearlman, K., Wan, W., Shah, S., & Laiteerapong, N. (2025) · JAMA Network Open

Electronic Health Records SystemsArtificial Intelligence in Healthcare and Education

Cited by 45

Serum thyrotropin and triiodothyronine levels in levothyroxine-treated patients

Ettleson, M. D., Prieto, W. H., Russo, P. S. T., de Sa, J., Wan, W., Laiteerapong, N., Maciel, R. M. B., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 25

Demographic, Healthcare Access, and Dietary Factors Associated With Thyroid Hormone Treatments for Hypothyroidism

Ettleson, M. D., Ibarra, S., Wan, W., Peterson, S., Laiteerapong, N., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 17

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults

Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 8